<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2091">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133947</url>
  </required_header>
  <id_info>
    <org_study_id>BCRG-CN-001</org_study_id>
    <nct_id>NCT05133947</nct_id>
  </id_info>
  <brief_title>Pre-study to Evaluate IENFD Induction in Patients With Taxane-induced CIPN</brief_title>
  <official_title>A Clinical Study Examining Intraepidermal Nerve Fiber Density (IENFD) in Patients With Chemotherapy-induced Peripheral Neuropathy (CIPN) Compared With Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional study examining IENFD levels in patients with CIPN after taxane&#xD;
      chemotherapy and in age-matched healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional study examining IENFD levels in patients with CIPN after taxane&#xD;
      chemotherapy and in age-matched healthy subjects. After the subjects sign the informed&#xD;
      consent, the study physicians will judge the inclusion and exclusion criteria. Subjects&#xD;
      meeting the inclusion requirements will register at the study center according to the&#xD;
      requirements of the study physicians, and skin samples will be collected by specialized&#xD;
      researchers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IENFD</measure>
    <time_frame>2021.10~2022.6</time_frame>
    <description>IENFD change between CIPN patients and healthy subjects</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Peripheral Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>CIPN patient</arm_group_label>
    <description>Patient with CIPN symptom</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subject</arm_group_label>
    <description>Healthy subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional</intervention_name>
    <description>Non interventional</description>
    <arm_group_label>CIPN patient</arm_group_label>
    <arm_group_label>Healthy subject</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        18-70 years old CIPN Patients and healthy subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Received taxane adjuvant chemotherapy for breast cancer for curative purposes and completed&#xD;
        chemotherapy before entering the study; Persistent peripheral neuropathy of the lower&#xD;
        extremities;&#xD;
&#xD;
        CIPN Severity:&#xD;
&#xD;
        The presence of at least one of the following symptoms on both lower extremities in a&#xD;
        gloved and sock glove pattern: pain or burning, numbness, or tingling.&#xD;
&#xD;
        Examination of the lower extremities showed needling loss of both legs; Neurological&#xD;
        symptoms occur after exposure to taxane and cannot be attributed to any other neurological&#xD;
        disease; NRS rating â‰¥ 4.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnant or lactating women. Presence of any neuropathy other than CIPN. According to the&#xD;
        investigator's judgment, there are skin diseases in the affected skin area that may&#xD;
        interfere with the evaluation of neuropathic pain symptoms, or diseases at the skin biopsy&#xD;
        site that may affect the epidermal nerve morphology, or other factors.&#xD;
&#xD;
        The presence of non-CIPN pain may interfere with study evaluation and/or peripheral&#xD;
        neuropathic pain self-assessment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Yan</last_name>
    <role>Study Chair</role>
    <affiliation>China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raylene Liu</last_name>
    <phone>+86 15862378343</phone>
    <email>raylene.liu@3ebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joanna Jiao</last_name>
    <email>joanna.jiao@3ebi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bethune First Hospital Of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojiao Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

